Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-05-19 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Earnings Release Classification · 85% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details a performance explanation meeting held on May 17, 2024, discussing the 2023 annual report results. The content includes Q&A about company R&D, fundraising project progress, market position, and industry outlook. The document is relatively short (2019 characters) and is a record of an investor relations event rather than the full annual report or earnings release itself. It is not a transcript of a call but a summary of an investor meeting focused on performance explanation. This fits best with the category of an Earnings Release (ER) or possibly an Investor Presentation (IP). However, since it is a Q&A session specifically described as a "业绩说明会" (performance explanation meeting), which is typically an earnings release or earnings presentation event, and given the short length and focus on 2023 annual results, the best fit is Earnings Release (ER). FY 2023
2024-05-19 Chinese
第三届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th meeting of the third Supervisory Board of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and references other announcements for further details. The content focuses on board-level decisions and meeting procedures rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial statements or earnings data, nor is it a proxy or voting result announcement. The document is best classified as Board/Management Information (MANG) because it reports on supervisory board meeting resolutions and governance matters.
2024-05-16 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the use of idle self-owned funds for cash management. It details the purpose, amount, investment methods, duration, risk analysis, and decision-making procedures related to the cash management plan. The document includes board and supervisory committee meeting resolutions and emphasizes compliance with disclosure obligations. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is a regulatory announcement about financing activities related to cash management and investment of idle funds. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (1541 characters), and it is not merely an announcement of a report but a substantive disclosure about financing activities.
2024-05-16 Chinese
关于召开2024年第二次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2024 second extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods, eligibility, agenda items, registration procedures, and contact information. It does not contain financial statements, audit results, or detailed management discussion. It is not a report but an announcement about a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly AGM Information (AGM-R). However, since this is a notice of the meeting itself (not the AGM but an extraordinary meeting), and it includes voting procedures and agenda, it aligns best with AGM Information (AGM-R) which covers presentations and materials shared during general meetings. The document length is short (2314 characters), consistent with a meeting notice rather than a full report. Hence, the classification is AGM-R with high confidence.
2024-05-16 Chinese
第三届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 3rd Board of Directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to related announcements on the stock exchange website. The content focuses on board meeting decisions and procedural compliance, without presenting financial statements or detailed management analysis. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is short (1391 characters), and it is not a report or a notice of report publication, so it is not an RPA or 10-K. Therefore, the classification is MANG with high confidence.
2024-05-16 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司使用部分闲置募集资金进行现金管理的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from the sponsor (长江证券承销保荐有限公司) regarding the use of idle raised funds by 浙江海昇药业股份有限公司. It includes specifics about the fundraising amount, usage progress, investment decisions, risk controls, and compliance with regulatory requirements. The document references regulatory approvals, fundraising details, and internal approvals but does not present financial statements or quarterly/yearly financial results. It is a specialized verification and opinion report on the use of raised funds for cash management, which aligns with an audit or verification type of report rather than a full annual or interim report. The document length is 3173 characters, which is relatively short but contains substantive content about the use of funds and compliance. It is not a simple announcement or certification but a formal verification opinion by the sponsor. Therefore, the best fitting category is Audit Report / Information (AR). Q1 2024
2024-05-16 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.